Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)

We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacio...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Lymphoma Myeloma Leuk
Main Authors: Ramos, Juan C., Sparano, Joseph A., Rudek, Michelle A., Moore, Page C., Cesarman, Ethel, Reid, Erin G., Henry, David, Ratner, Lee, Aboulafia, David, Lee, Jeanette Y., Ambinder, Richard F., Mitsuyasu, Ronald, Noy, Ariela
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697160/
https://ncbi.nlm.nih.gov/pubmed/29426719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2018.01.004
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker